# IVIG for Infection Prevention After CAR-T-Cell Therapy

> **NCT05952804** · PHASE2 · RECRUITING · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 150 (estimated)

## Conditions studied

- Hematologic Malignancies

## Interventions

- **BIOLOGICAL:** Immune Globulin Infusion (Human), 10% Solution
- **BIOLOGICAL:** Anti-CD19 CAR T Cells Preparation
- **OTHER:** Saline
- **PROCEDURE:** Biospecimen Collection
- **OTHER:** Survey Administration
- **OTHER:** Electronic Health Record Review

## Key facts

- **NCT ID:** NCT05952804
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-06-10
- **Primary completion:** 2028-07-31
- **Final completion:** 2028-07-31
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2026-04-21

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05952804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05952804, "IVIG for Infection Prevention After CAR-T-Cell Therapy". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05952804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*